Search results
Results from the WOW.Com Content Network
ABC excluded the entire PFS Program from its standard regulatory audit and pedigree compliance programs. [32] [33] AmerisourceBergen's stock price reportedly plummeted after they were among other drug distributors who offered $10 billion to settle their portion of the national opioids lawsuit. [34] [35] States countered with $45 billion. [36]
AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
AmerisourceBergen (ABC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1961 or 1962 (age 62–63) [1] South Africa. Title. Chairman, president and CEO, AmerisourceBergen. Predecessor. R. David Yost. Successor. incumbent. Steven H. Collis (born 1961) is an American businessman, the chairman, president and chief executive officer (CEO) of Cencora, previously known as AmerisourceBergen. [2][3][4][5]
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
AmerisourceBergen (ABC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.